
"

Interleukin 11 Receptor (IL-11R)



Ļ

SEQ IDNO.3

cDNA sequence inserted to generate soluble IL-11R

٠. ا Ü 11 12

ATGAGCAGC AGCTGCTCAG GGCTGAGCAG GGTCCTGGTG GCCGTGGCTA CAGCCCTGGT GTCTGCCTCC TCCCCCTGCC CCCAGGCCTG GGGCCCCCCA GGGGTCCAGT ATGGGCAGCC Figure 1 B AGGGAGGTCC GTGAAGCTGT GTTGTCCTGG AGTGACTGCC GGGGACCCAG TGTCCTGGTT TCGGGATGGG GAGCCAAAGC TGCTCCAGGG ACCTGACTCT GGGCTAGGGC ATGAACTGGT CCTGGCCCAG GCAGACAGCA CTGATGAGGG CACCTACATC TGCCAGACCC TGGATGGTGC ACTTGGGGGC ACAGTGACCC TGCAGCTGGG CTACCCTCCA GCCCGCCCTG TTGTCTCCTG CCAAGCAGCC GACTATGAGA ACTTCTCTTG CACTTGGAGT CCCAGCCAGA TCAGCGGTTT ACCCACCCGC TACCTCACCT CCTACAGGAA GAAGACAGTC CTAGGAGCTG ATAGCCAGAG GAGGAGTCCA TCCACAGGGC CCTGGCCATG CCCACAGGAT CCCCTAGGGG CTGCCCGCTG TGTTGTCCAC GGGGCTGAGT TCTGGAGCCA GTACCGGATT AATGTGACTG AGGTGAACCC ACTGGTGCC AGCACACGCC TGCTGGATGT GAGCTTGCAG AGCATCTTGC GCCCTGACCC ACCCCAGGGC CTGCGGGTAG AGTCAGTACC AGGTTACCCC CGACGCCTGC GAGCCAGCTG GACATACCCT GCCTCCTGGC CGTGCCAGCC CCACTTCCTG CTCAAGTTCC GTTTGCAGTA CCGTCCGGCG CAGCATCCAG CCTGGTCCAC GGTGGAGCCA GCTGGACTGG AGGAGGTGAT CACAGATGCT GTGGCTGGGC TGCCCCATGC TGTACGAGTC AGTGCCCGGG ACTTTCTAGA TGCTGGCACC TGGAGCACCT GGAGCCCGGA GGCCTGGGGA ACTCCGAGCA CTGGGACCAT ACCAAAGGAG ATACCAGCAT GGGGCCAGCT ACACACGCAG CCAGAGGTGG AGCCTCAGGT GGACAGCCCT GCTCCTCCAA GGCCCTCCCT CCAACCACAC CCTCGGCTAC TTGATCACAG GGACTCTGTG GAGCAGCTGG TGCCACGCGG TTCTCATCAC CATCATCACC ACTGA

Figure 2

gp 130 binding region

282 283 284 285 186 287 288 289 290 291
$$- V - A - V - A - G - L - P - H - A - V - Native$$

$$\downarrow \qquad \qquad \downarrow \qquad \qquad \downarrow \qquad \qquad \downarrow \qquad \qquad \downarrow$$

$$- G - P - V - A - D - L - P - Y - A - L - Mutant 3 = Q = D^{C}$$

Human Interleukin 11 Receptor Protein Sequence

MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCP RVSARDFLDAGTWSTWSPEAWGTPSTGTIPKEIPAWGOLHTOPEVEPOV *JGALGGTVTLQLGYPPARPVVSCQAADYENFSCTWSPSQISGLPTRYLT* SYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARCVVHGAEFWSOYRIN VTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASWTYP GVTAGDPVSWFRDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICOTL **ASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAV** DSPAPPRPSLQPHPRLLDHRDSVEQVAVLASLGILSFLGLVAGALALGL WLRRRGGKDGSPKPGFLASVIPVDRRPGAPNL

** Bolded amino acids:

Human Interleukin 11 Receptor protein sequence that interacts with Interleukin 11

Inhibitory Peptide

Peptide Peptide Sequence 1 RRLRASWTYPASWPCQPHFL 2 TYPASWPCQPHFLLKFRLQY				
RRLRASWTYPASWPCQPHFL TYPASWPCQPHFLLKFRLQY		Peptide	Peptide Sequence	Antagonistic Activity
2 TYPASWPCQPHFLLKFRLQY	100 PG	1	RRLRASWTYPASWPCQPHFL	yes
	ID NO		TYPASWPCQPHFLLKFRLQY	no

Figure 5

The Effect of Murine Interleukin-11 on Bone Nodule Formation




Figure 6 A




Figure 6 B

THE RESERVE AND THE RESERVE AND THE PERSON OF THE PERSON O






Figure 6 C








Figure 8




Figure 9





Figure 10



rlL-11 Concentration ng/ml	Number of Trap+ Cells/Well
0.0	0.0 ± 0.0
3.1	1.0 ± 0.5
6.3	26.5 ± 15.8
12.5	140.8 ± 25.2
25.0	273.3 ± 24.0
50.0	395.5 ± 35.6

The effect of IL-11 on osteoclast development in cocultures of murine bone marrow and calvaria cells. Cocultures of marrow and calvaria cells were maintained in the absence or presence of increasing concentrations of IL-11. Nine days later the cells were stained for TRAPase activity and the number of multinucleated TRAP+ cells determined. Data are expressed as mean \pm SEM, * p < 0.05 when compared with the number of TRAP+ cells counted in the absence of rIL-1 $\mbox{\sc l}$.